Looking for a Simplified Diagnostic Model to Identify Potentially Lethal Cases of Prostate Cancer at Initial Diagnosis: An ImGO Pilot Study.
cribriform pattern
intraductal carcinoma
metastatic castration-resistant prostate cancer
metastatic castration-sensitive prostate cancer
phenotypic markers
prostate cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Mar 2022
17 Mar 2022
Historique:
received:
21
01
2022
revised:
11
03
2022
accepted:
12
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
The recurrent genetic anomalies used to classify prostate cancer (PC) into distinct molecular subtypes have limited relevance for clinical practice. In consideration of WHO 2016 histological classification, which includes the introduction of Gleason Score 4 for patients with cribriform component and the definition of intraductal carcinoma as a new entity, a retrospective pilot study was conducted to investigate, by histological review, if there were any variations of Gleason Score and the incidence of intraductal carcinoma and cribriform pattern, intended as "phenotypic" markers of potentially lethal PC, among metastatic castration-sensitive PC (mCSPC) and metastatic castration-resistant PC (mCRPC) samples. Potentially predictive factors were also assessed. Among 125 cases, a variation in the Gleason Score was reported in 26% of cases. A cribriform (36%) or intraductal (2%) pattern was reported in a higher percentage. Of them, a primary Gleason pattern 4 was reported in 80% of cases. All patients with intraductal carcinoma present a
Identifiants
pubmed: 35326693
pii: cancers14061542
doi: 10.3390/cancers14061542
pmc: PMC8946832
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Mol Cancer Ther. 2020 Jun;19(6):1373-1382
pubmed: 32220973
BJU Int. 2015 Feb;115(2):248-55
pubmed: 24552193
Mod Pathol. 2018 Jan;31(S1):S143-155
pubmed: 29297492
J Clin Invest. 2019 Jul 30;129(10):4492-4505
pubmed: 31361600
Arch Pathol Lab Med. 2007 Jul;131(7):1103-9
pubmed: 17616999
J Clin Oncol. 2019 Nov 10;37(32):2961-2967
pubmed: 31498754
Genes Dev. 2018 Sep 1;32(17-18):1105-1140
pubmed: 30181359
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
Transl Androl Urol. 2018 Feb;7(1):145-154
pubmed: 29594028
Asian Pac J Cancer Prev. 2007 Jul-Sep;8(3):422-8
pubmed: 18159981
Eur Urol. 2018 Apr;73(4):572-582
pubmed: 29129398
Am J Surg Pathol. 2005 Sep;29(9):1228-42
pubmed: 16096414
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Eur Urol Oncol. 2018 May;1(1):21-28
pubmed: 31100224
Mod Pathol. 2013 Apr;26(4):587-603
pubmed: 23222491
Cell. 2018 Jul 26;174(3):758-769.e9
pubmed: 30033370
Pathobiology. 2018;85(1-2):108-116
pubmed: 29393241
Cell Rep. 2020 May 26;31(8):107669
pubmed: 32460015
Cancer J. 2011 Nov-Dec;17(6):429-37
pubmed: 22157287
J Natl Cancer Inst. 2005 Sep 7;97(17):1248-53
pubmed: 16145045
Ann Oncol. 2017 Oct 1;28(10):2472-2480
pubmed: 28961847
Saudi Med J. 2020 Jan;41(1):9-17
pubmed: 31915789
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Prostate. 2019 Aug;79(11):1267-1273
pubmed: 31111513
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28825054
Eur Urol. 2015 Mar;67(3):496-503
pubmed: 25154392